Bel-Mar
As of the edition of 20 October 2026, Bel-Mar runs 2 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyanocobalamin | none listed | 0 |
| Gonadotropin, chorionic | Ended 1985 (computed from the first US licence) | 0 |
A route B row is one company at one target.